Comparative antineoplastic activity of adriamycin and N-trifluoroacetyladriamycin-14-valerate

A. Vecchi, M. Cairo, A. Mantovani, M. Sironi, F. Spreafico

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

A comparative investigation of the antineoplastic activity of adriamycin and its derivative, N-trifluoroacetyladriamycin-14-valerate (AD 32), was conducted in murine tumor models employing different treatment schedules and injection routes. In all conditions tested, i.e., ascitic and disseminated L1210 leukemia, ascitic LSTRA lymphoma, and advanced Lewis lung carcinoma, AD 32 was significantly more effective in terms of lifespan prolongation and induction of cures than optimal adriamycin treatments. As with adriamycin, AD 32 was ineffective on ic transplanted L1210 leukemia.

Original languageEnglish
Pages (from-to)111-117
Number of pages7
JournalCancer Treatment Reports
Volume62
Issue number1
Publication statusPublished - 1978

Fingerprint

valrubicin
Antineoplastic Agents
Doxorubicin
Leukemia L1210
Lewis Lung Carcinoma
Lymphoma
Appointments and Schedules
Injections
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Comparative antineoplastic activity of adriamycin and N-trifluoroacetyladriamycin-14-valerate. / Vecchi, A.; Cairo, M.; Mantovani, A.; Sironi, M.; Spreafico, F.

In: Cancer Treatment Reports, Vol. 62, No. 1, 1978, p. 111-117.

Research output: Contribution to journalArticle

@article{1851421361a7449db4804f2ccf7d3f45,
title = "Comparative antineoplastic activity of adriamycin and N-trifluoroacetyladriamycin-14-valerate",
abstract = "A comparative investigation of the antineoplastic activity of adriamycin and its derivative, N-trifluoroacetyladriamycin-14-valerate (AD 32), was conducted in murine tumor models employing different treatment schedules and injection routes. In all conditions tested, i.e., ascitic and disseminated L1210 leukemia, ascitic LSTRA lymphoma, and advanced Lewis lung carcinoma, AD 32 was significantly more effective in terms of lifespan prolongation and induction of cures than optimal adriamycin treatments. As with adriamycin, AD 32 was ineffective on ic transplanted L1210 leukemia.",
author = "A. Vecchi and M. Cairo and A. Mantovani and M. Sironi and F. Spreafico",
year = "1978",
language = "English",
volume = "62",
pages = "111--117",
journal = "Cancer Treatment Reports",
issn = "0361-5960",
publisher = "U.S. National Cancer Institute",
number = "1",

}

TY - JOUR

T1 - Comparative antineoplastic activity of adriamycin and N-trifluoroacetyladriamycin-14-valerate

AU - Vecchi, A.

AU - Cairo, M.

AU - Mantovani, A.

AU - Sironi, M.

AU - Spreafico, F.

PY - 1978

Y1 - 1978

N2 - A comparative investigation of the antineoplastic activity of adriamycin and its derivative, N-trifluoroacetyladriamycin-14-valerate (AD 32), was conducted in murine tumor models employing different treatment schedules and injection routes. In all conditions tested, i.e., ascitic and disseminated L1210 leukemia, ascitic LSTRA lymphoma, and advanced Lewis lung carcinoma, AD 32 was significantly more effective in terms of lifespan prolongation and induction of cures than optimal adriamycin treatments. As with adriamycin, AD 32 was ineffective on ic transplanted L1210 leukemia.

AB - A comparative investigation of the antineoplastic activity of adriamycin and its derivative, N-trifluoroacetyladriamycin-14-valerate (AD 32), was conducted in murine tumor models employing different treatment schedules and injection routes. In all conditions tested, i.e., ascitic and disseminated L1210 leukemia, ascitic LSTRA lymphoma, and advanced Lewis lung carcinoma, AD 32 was significantly more effective in terms of lifespan prolongation and induction of cures than optimal adriamycin treatments. As with adriamycin, AD 32 was ineffective on ic transplanted L1210 leukemia.

UR - http://www.scopus.com/inward/record.url?scp=0018181271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018181271&partnerID=8YFLogxK

M3 - Article

C2 - 626989

AN - SCOPUS:0018181271

VL - 62

SP - 111

EP - 117

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

SN - 0361-5960

IS - 1

ER -